Rebecca Paschall
Family · Fort Pierce, FLNPI 1770590333
Payments from drug & device makers
Across 162 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$289
- Pfizer$286
- Exact Sciences$193
- Astellas Pharma US Inc$191
- Dexcom, Inc.$184
- Bayer$182
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,12695%
- Education$1775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 17 | $289 |
| Pfizer | 14 | $286 |
| Exact Sciences | 9 | $193 |
| Astellas Pharma US Inc | 8 | $191 |
| Dexcom, Inc. | 7 | $184 |
| Bayer | 9 | $182 |
| Abbott | 8 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $178 |
| AstraZeneca | 8 | $175 |
| Boehringer Ingelheim | 5 | $173 |
| Amgen | 9 | $159 |
| Actelion Pharmaceuticals US, Inc. | 3 | $133 |
| AbbVie | 7 | $119 |
| Novartis | 6 | $116 |
| GSK | 6 | $105 |
| Novo Nordisk | 7 | $102 |
| Merck | 5 | $93 |
| Boston Scientific | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Johnson & Johnson | 3 | $47 |
| Corcept Therapeutics | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Corium, LLC | 2 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,303 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $36,150 |
| Atorvastatin Calcium | 85 | $727 |
| Metoprolol Tartrate | 16 | $487 |
| Amlodipine Besylate | 54 | $377 |
| Levothyroxine Sodium | 41 | $363 |
| Rosuvastatin Calcium | 16 | $247 |
| Trazodone Hcl | 14 | $215 |
| Gabapentin | 15 | $214 |
| Lisinopril | 45 | $197 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $155 |
| Methylprednisolone | 18 | $152 |
| Losartan Potassium | 23 | $148 |
| Pantoprazole Sodium | 14 | $139 |
| Famotidine | 13 | $135 |
| Metformin Hcl | 22 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $36,15034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Fort Pierce
- Marta EuleFort Pierce$91K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.